Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Thermo Fisher ScientificBSP:TMOS34 +0.74%74 EV-to-EBIT is 26.10 as of Jul. 17, 2026, which is 13% below its 10-year median of 29.84. GuruFocus rates BSP:TMOS34 with a GF Score™ of 74/100 and a GF Value™ of R$61.73 (Fairly Valued). The stock has 5 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Thermo Fisher Scientific ranks worse than 64.42% on this metric.
The historical rank and industry rank for Thermo Fisher Scientific's EV-to-EBIT or its related term are showing as below:
BSP:TMOS34'
s EV-to-EBIT Range Over the Past 10 Years
Min: 19.7 Med: 29.84 Max: 41.46
Current: 27.2
During the past 13 years, the highest EV-to-EBIT of Thermo Fisher Scientific was 41.46. The lowest was 19.70. And the median was 29.84.
BSP:TMOS34's EV-to-EBIT is ranked worse than 64.42% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.035
vs BSP:TMOS34: 27.20
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Thermo Fisher Scientific's Enterprise Value for the quarter that ended in Mar. 2026 was R$1,157,794 Mil.
Thermo Fisher Scientific's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$48,029 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific EV-to-EBIT Related Terms
Thermo Fisher Scientific EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Thermo Fisher Scientific's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thermo Fisher Scientific EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Thermo Fisher Scientific's EV-to-EBIT falls into.
Thermo Fisher Scientific's current Enterprise Value is R$1,253,486 Mil.
Thermo Fisher Scientific's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$48,029 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thermo Fisher Scientific (BSP:TMOS34) has a EV-to-EBIT of 26.10 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Thermo Fisher Scientific and its competitors. This is 13% below median its historical median of 29.84. Over the past decade, Thermo Fisher Scientific's EV-to-EBIT has ranged from 19.70 to 41.46. According to the industry distribution chart, Thermo Fisher Scientific ranks #67 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 64.4%.
Is Thermo Fisher Scientific's EV-to-EBIT too high?
Thermo Fisher Scientific's current EV-to-EBIT of 26.10 is 13% below median its 10-year median of 29.84. Over the past 10 years, this metric has ranged from a low of 19.70 to a high of 41.46. The Medical Diagnostics & Research industry median EV-to-EBIT is 23.04. Thermo Fisher Scientific's value of 26.10 is 13.3% above this industry median. Based on the distribution chart, Thermo Fisher Scientific ranks #67 out of 104 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Thermo Fisher Scientific has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's EV-to-EBIT compare to DHR and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Thermo Fisher Scientific ranks #67 out of 104 companies for EV-to-EBIT. This places Thermo Fisher Scientific in the lower half of its industry. The industry median EV-to-EBIT is 23.04. Thermo Fisher Scientific's value of 26.10 is 13.3% above this benchmark. Historically, Thermo Fisher Scientific's own EV-to-EBIT has ranged from 19.70 to 41.46 over the past decade. While the company's 10-year median is 29.84 vs. the industry median of 23.04, Thermo Fisher Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.04, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thermo Fisher Scientific's current EV-to-EBIT of 26.10 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Thermo Fisher Scientific and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thermo Fisher Scientific's current EV-to-EBIT is 26.10, which is 13% below median its own 10-year median of 29.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (BSP:TMOS34) is currently considered Fairly Valued. The stock's GF Value™ is R$61.73, compared to a current price of R$57.21 — trading 7.3% below its estimated fair value. The current EV-to-EBIT is 26.10, which is 13% below median its 10-year median of 29.84 and 13.3% above the Medical Diagnostics & Research industry median of 23.04. Thermo Fisher Scientific's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Thermo Fisher Scientific (BSP:TMOS34), the current EV-to-EBIT is 26.10 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thermo Fisher Scientific (BSP:TMOS34) Overvalued in 2026?
Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued.
The current stock price of R$57.21 is trading 7.3% below its estimated GF Value™ of R$61.73.
GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.
Key valuation signals for BSP:TMOS34:
EV-to-EBIT: 26.10 (13% below median its 10-year median of 29.84)
GF Value™: R$61.73 vs. price of R$57.21 (7.3% below fair value)
Industry Position: 13.3% above the Medical Diagnostics & Research median (#67 of 104)
No single metric tells the full story. See the BSP:TMOS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
74GF Score
Get the complete analysis for BSP:TMOS34
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:TMOS34 has been successfully added to your 
